Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination

Overview

Journal Medicines (Basel)

Specialty Pharmacology

Date 2025 Feb 21

PMID 39982324

Authors

Hiep X Nguyen

Affiliations

Soon will be listed here.

Abstract

Vaccination represents a critical preventive strategy in the current global healthcare system, serving as an indispensable intervention against diverse pathogenic threats. Although conventional immunization relies predominantly on hypodermic needle-based administration, this method carries substantial limitations, including needle-associated fear, bloodborne pathogen transmission risks, occupational injuries among healthcare workers, waste management issues, and dependence on trained medical personnel. Microneedle technology has emerged as an innovative vaccine delivery system, offering convenient, effective, and minimally invasive administration. These microscale needle devices facilitate targeted antigen delivery to epidermal and dermal tissues, where abundant populations of antigen-presenting cells, specifically Langerhans and dermal dendritic cells, provide robust immunological responses. Multiple research groups have extensively investigated microneedle-based vaccination strategies. This transdermal delivery technique offers several advantages, notably circumventing cold-chain requirements and enabling self-administration. Numerous preclinical investigations and clinical trials have demonstrated the safety profile, immunogenicity, and patient acceptance of microneedle-mediated vaccine delivery across diverse immunization applications. This comprehensive review examines the fundamental aspects of microneedle-based immunization, including vaccination principles, transcutaneous immunization strategies, and microneedle-based transdermal delivery-including classifications, advantages, and barriers. Furthermore, this review addresses critical technical considerations, such as treatment efficacy, application methodologies, wear duration, dimensional optimization, manufacturing processes, regulatory frameworks, and sustainability considerations, followed by an analysis of the future perspective of this technology.

References

Korkmaz E, Balmert S, Sumpter T, Donahue Carey C, Erdos G, Falo Jr L . Microarray patches enable the development of skin-targeted vaccines against COVID-19. Adv Drug Deliv Rev. 2021; 171:164-186. PMC: 8060128. DOI: 10.1016/j.addr.2021.01.022. View

Fine P, Eames K, Heymann D . "Herd immunity": a rough guide. Clin Infect Dis. 2011; 52(7):911-6. DOI: 10.1093/cid/cir007. View

Lin Y, Zimmermann J, Schulke S . Novel adjuvants in allergen-specific immunotherapy: where do we stand?. Front Immunol. 2024; 15:1348305. PMC: 10920236. DOI: 10.3389/fimmu.2024.1348305. View

Arya J, DeWitt K, Scott-Garrard M, Chiang Y, Prausnitz M . Rabies vaccination in dogs using a dissolving microneedle patch. J Control Release. 2016; 239:19-26. DOI: 10.1016/j.jconrel.2016.08.012. View

Edens C, Collins M, Goodson J, Rota P, Prausnitz M . A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine. 2015; 33(37):4712-8. PMC: 4554796. DOI: 10.1016/j.vaccine.2015.02.074. View

Nguyen H, Banga A . Electrically and Ultrasonically Enhanced Transdermal Delivery of Methotrexate. Pharmaceutics. 2018; 10(3). PMC: 6161078. DOI: 10.3390/pharmaceutics10030117. View

Guimaraes T, Moniz T, Nunes C, Zaharieva M, Kaleva M, Yoncheva K . Polymeric Microneedles for Transdermal Delivery of Rivastigmine: Design and Application in Skin Mimetic Model. Pharmaceutics. 2022; 14(4). PMC: 9028500. DOI: 10.3390/pharmaceutics14040752. View

Pabst R . Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences. Vaccine. 2015; 33(36):4406-13. DOI: 10.1016/j.vaccine.2015.07.022. View

Kim W, Roberts C, Song J, Yoon J, Seong H, Hyun H . Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device. Int J Infect Dis. 2023; 128:112-120. PMC: 9803371. DOI: 10.1016/j.ijid.2022.12.037. View

10.

Hogan M, Kikuta A, Taddio A . A systematic review of measures for reducing injection pain during adult immunization. Vaccine. 2009; 28(6):1514-21. DOI: 10.1016/j.vaccine.2009.11.065. View

11.

Prausnitz M . Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin. Annu Rev Chem Biomol Eng. 2017; 8:177-200. DOI: 10.1146/annurev-chembioeng-060816-101514. View

12.

Portnoy A, Ozawa S, Grewal S, Norman B, Rajgopal J, Gorham K . Costs of vaccine programs across 94 low- and middle-income countries. Vaccine. 2015; 33 Suppl 1:A99-108. DOI: 10.1016/j.vaccine.2014.12.037. View

13.

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

14.

Iwata H, Kakita K, Imafuku K, Takashima S, Haga N, Yamaguchi Y . Safety and dose-sparing effect of Japanese encephalitis vaccine administered by microneedle patch in uninfected, healthy adults (MNA-J): a randomised, partly blinded, active-controlled, phase 1 trial. Lancet Microbe. 2022; 3(2):e96-e104. DOI: 10.1016/S2666-5247(21)00269-X. View

15.

Burton S, Ng C, Simmers R, Moeckly C, Brandwein D, Gilbert T . Rapid intradermal delivery of liquid formulations using a hollow microstructured array. Pharm Res. 2010; 28(1):31-40. PMC: 3003827. DOI: 10.1007/s11095-010-0177-8. View

16.

Lee K, Jeong S, Roh D, Kim D, Choi H, Lee E . A practical guide to the development of microneedle systems - In clinical trials or on the market. Int J Pharm. 2019; 573:118778. DOI: 10.1016/j.ijpharm.2019.118778. View

17.

Kim E, Erdos G, Huang S, Kenniston T, Balmert S, Donahue Carey C . Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020; 55:102743. PMC: 7128973. DOI: 10.1016/j.ebiom.2020.102743. View

18.

Mikszta J, Alarcon J, Brittingham J, Sutter D, Pettis R, Harvey N . Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med. 2002; 8(4):415-9. DOI: 10.1038/nm0402-415. View

19.

Kutzler M, Weiner D . DNA vaccines: ready for prime time?. Nat Rev Genet. 2008; 9(10):776-88. PMC: 4317294. DOI: 10.1038/nrg2432. View

20.

Caudill C, Perry J, Iliadis K, Tessema A, Lee B, Mecham B . Transdermal vaccination via 3D-printed microneedles induces potent humoral and cellular immunity. Proc Natl Acad Sci U S A. 2021; 118(39). PMC: 8488660. DOI: 10.1073/pnas.2102595118. View